
Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) recently announced updates to the ongoing development of its lead oncology program, IMM-ONC-01, a novel immuno-oncology agent that inhibits IL-38, an immunosuppressive cytokine.
Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38 Read More